NO974956L - Therapeutic composition for arthritis - Google Patents
Therapeutic composition for arthritisInfo
- Publication number
- NO974956L NO974956L NO974956A NO974956A NO974956L NO 974956 L NO974956 L NO 974956L NO 974956 A NO974956 A NO 974956A NO 974956 A NO974956 A NO 974956A NO 974956 L NO974956 L NO 974956L
- Authority
- NO
- Norway
- Prior art keywords
- arthritis
- agent
- administration
- inflammatory
- acting
- Prior art date
Links
- 206010003246 arthritis Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 4
- 230000000202 analgesic effect Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- 150000003431 steroids Chemical class 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det blir fremskaffet et farmasøytisk middel som viser hurtigvirkende og vedvarende anti-inflammatorisk analgesisk virkning mot kronisk artritis med lav fremtreden av bieffekter. En farmasøytisk sammensetning omfattende en kombinasjon av et quinolin-/quina- zolinserier profylaktisk/terapeutisk middel for artritis og hurtigvirkende anti-inflam- matorisk analgesisk middel omfattende (1) en cyklooksygenaseinhibitor, (2) et sentralt analgesika, (3) et steroid eller (4) et anti-inflammatorisk enzym-middel. Foreliggende preparat viser utmerkede effekter mot artritis fra administrasjon for å sikre stabil anti-inflammatorisk analgesisk virkning med lav fremtreden av bieffekter selv ved kronisk administrasjon, forutsatt at medikamentsammensetning, administrasjonsmetode og dose er passende valgt ifølge symptomene.A pharmaceutical agent is provided which shows fast-acting and sustained anti-inflammatory analgesic action against chronic arthritis with a low onset of side effects. A pharmaceutical composition comprising a combination of a quinoline / quinazoline series prophylactic / therapeutic agent for arthritis and fast-acting anti-inflammatory analgesic agent comprising (1) a cyclooxygenase inhibitor, (2) a central analgesic, (3) a steroid or ( 4) an anti-inflammatory enzyme agent. The present preparation shows excellent effects against arthritis from administration to ensure stable anti-inflammatory analgesic effect with low appearance of side effects even in chronic administration, provided that drug composition, administration method and dose are appropriately selected according to the symptoms.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10631695 | 1995-04-28 | ||
| JP27085695 | 1995-10-19 | ||
| PCT/JP1996/001102 WO1996033717A1 (en) | 1995-04-28 | 1996-04-24 | Therapeutic composition for arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO974956L true NO974956L (en) | 1997-10-27 |
| NO974956D0 NO974956D0 (en) | 1997-10-27 |
Family
ID=26446436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO974956A NO974956D0 (en) | 1995-04-28 | 1997-10-27 | Therapeutic composition for arthritis |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0830133A1 (en) |
| KR (1) | KR19990008148A (en) |
| AU (1) | AU715358B2 (en) |
| CA (1) | CA2216138A1 (en) |
| HU (1) | HUP9801628A2 (en) |
| NO (1) | NO974956D0 (en) |
| WO (1) | WO1996033717A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262269B1 (en) | 1997-02-04 | 2001-07-17 | Trega Biosciences, Inc. | 4-Substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries |
| CA2279977A1 (en) * | 1997-02-04 | 1998-08-06 | John S. Kiely | 4-substituted-quinoline derivatives and 4-substituted-quinoline combinatorial libraries |
| DE60129445T2 (en) | 2000-08-09 | 2008-04-24 | F. Hoffmann-La Roche Ag | QUINOLINE DERIVATIVES AS AN ANTI-INFLAMMATORY AGENT |
| EP1354603A1 (en) * | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968701A (en) * | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
| DE68908459T2 (en) * | 1988-04-26 | 1994-04-07 | Asahi Glass Co Ltd | Prepolymer composition, process for its preparation and its use. |
| US5187180A (en) * | 1990-07-26 | 1993-02-16 | Merck Frosst Canada, Inc. | (quinolin-2-ylmethoxy)heterotetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes |
| IE920499A1 (en) * | 1991-02-21 | 1992-08-26 | Merck Frosst Canada Inc | Quinoline-containing ketoacids as leukotriene antagonists |
| TW232013B (en) * | 1992-04-24 | 1994-10-11 | Takeda Pharm Industry Co Ltd | |
| KR100224135B1 (en) * | 1993-01-28 | 1999-10-15 | 다께다 구니오 | Quinoline or quinazoline derivatives, preparations and uses thereof |
| US5641788A (en) * | 1994-06-07 | 1997-06-24 | Takeda Chemical Industries, Ltd. | Quinoline derivatives and pharmaceutical composition containing them |
-
1996
- 1996-04-24 AU AU55136/96A patent/AU715358B2/en not_active Ceased
- 1996-04-24 EP EP96912213A patent/EP0830133A1/en not_active Withdrawn
- 1996-04-24 WO PCT/JP1996/001102 patent/WO1996033717A1/en not_active Ceased
- 1996-04-24 KR KR1019970707673A patent/KR19990008148A/en not_active Withdrawn
- 1996-04-24 CA CA002216138A patent/CA2216138A1/en not_active Abandoned
- 1996-04-24 HU HU9801628A patent/HUP9801628A2/en unknown
-
1997
- 1997-10-27 NO NO974956A patent/NO974956D0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2216138A1 (en) | 1996-10-31 |
| AU715358B2 (en) | 2000-01-20 |
| WO1996033717A1 (en) | 1996-10-31 |
| KR19990008148A (en) | 1999-01-25 |
| AU5513696A (en) | 1996-11-18 |
| HUP9801628A2 (en) | 1999-01-28 |
| EP0830133A1 (en) | 1998-03-25 |
| NO974956D0 (en) | 1997-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1637A (en) | Celecoxib compositions. | |
| BR0013704A (en) | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases | |
| NO922004D0 (en) | ORAL PREPARATION FOR TREATMENT OF INFLAMMATORY GAS DISORDERS | |
| NO934284L (en) | Pharmaceutical preparation containing a defined lipid system | |
| SE9704870D0 (en) | New pharmaceutical formulation I | |
| ATE486840T1 (en) | MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF | |
| ATE277596T1 (en) | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A CHOLINERGIC ACT OR A CALCIUM CHANNEL BLOCKER | |
| WO1998019649A3 (en) | Methods and compositions for inhibition of angiogenesis | |
| SE9602442D0 (en) | Administration of pharmaceuticals | |
| BR9810520A (en) | Factor xa inhibitor alone or in combination with an anti-platelet aggregator, against arterial thrombosis | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| NO954878L (en) | pyrrole | |
| WO2000033790A3 (en) | Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs | |
| BR9813179A (en) | Extended release formulation | |
| ES2126123T3 (en) | USE OF CINEOL OR MENTHOL FOR THE TREATMENT OF ASTHMA. | |
| BR9803233A (en) | Preparation of a pharmaceutical combination of a sodium / hydrogen exchanger inhibitor and a drug for the treatment of cardiovascular diseases. | |
| NO974956L (en) | Therapeutic composition for arthritis | |
| AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
| DK0862454T3 (en) | CTLA-8 in combination with G-CSF or with G-CSF and IL-6 and use of CTLA-8 to treat infections | |
| NO952234L (en) | Transdermal administration system containing acetylsalicylic acid for antithrombosis therapy and cancer prevention | |
| NO962503L (en) | Use of penoxyphylline in the treatment of multiple sclerosis | |
| NO20050933L (en) | Pravastatin pharmaceutical formulations and methods for their use | |
| EA199700025A1 (en) | APPLICATION OF OLIGOSACCHARIDE AND ASPIRIN TO PREPARATION OF MEDICINES INTENDED FOR THE TREATMENT OF THROMBOEMBOLIC DISEASES, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT | |
| AR033424A1 (en) | PHARMACEUTICAL COMPOSITIONS | |
| BR0010449A (en) | 14beta-h-sterols, pharmaceutical compositions comprising the same and use of these derivatives for the preparation of meiosis regulating drugs |